The European dental bone graft substitute (DBGS) market valuation was €151 million in 2020. In comparison to 2019, the valuation of the market in 2020 was 31% lower due to COVID-19. Despite this, the market is growing steadily and many expect it to reach €277.2 million by 2027.
WHICH SEGMENTS ARE A PART OF THE EUROPEAN DENTAL BONE GRAFT SUBSTITUTE ANALYSIS?
These are bone graft materials taken from the patient’s own body. Autograft harvesting involves the transplantation of the patient’s bone or tissue to the area of their body in need.
There are two types of allograft materials: freeze-dried bone allograft (FDBA) and demineralized freeze-dried bone allografts (DFDBA).
Mineralized allografts are bone graft materials harvested from human donors.
Demineralized Bone Matrix Allografts
Demineralized bone matrix materials are a unique type of allograft. This category includes demineralized freeze-dried bone allografts, either with or without a carrier.
Xenografts are bone graft substitutes derived from animal species other than humans.
Synthetic bone graft substitute materials do not come from animal or human sources.
WHAT ARE THE LARGEST AND SMALLEST DBGS MARKET SEGMENTS?
The total market value for dental bone graft substitutes (DBGS) dropped significantly in 2020 due to sharp contractions in economic activity triggered by the COVID-19 pandemic. Regardless, industry leaders are confident that their business fundamentals remain intact, and they foresee a swift recovery for the market.
Xenografts are currently the largest market segment. Over the forecast period and into 2027, this segment is to remain the predominant segment. Although xenograft materials pose a disease transmission risk, the supply and accessibility of their use are much higher relative to human donor allograft materials across Europe. In terms of growth, increasing unit sales will be the main driver. A modest depreciation in the average selling prices (ASPs) will be limiting this market. While it is true that this segment will maintain its dominant position, it will experience a persistent decline in its share of the total DBGS market.
On the other hand, the synthetic market is the smallest market segment. Synthetic materials typically cater to patients who seek to avoid an additional surgical procedure to harvest their autograft material for a bone grafting procedure. Despite being the smallest market segment, the synthetic market is experiencing relatively moderate growth since it caters to a specific niche market across Europe. In terms of growth, increasing unit sales, and modest ASP appreciation will be the main drivers.
WHAT COMPANIES ARE COMPETING IN THE OVERALL MARKET?
Geistlich, Botiss Biomaterials, and Zimmer Biomet are the three market leaders.
In 2020, Geistlich maintained its leading position in the European dental bone graft substitute market. The company only participated in the xenograft market, where it continued to have a dominating presence with well over 50% of the total market value. Geistlich benefits from a strong foundation in scientific research and an extensive product base. The company also sells the most recognized brands of dental bone graft material, Bio-Oss® xenografts, and Bio-Gide® dental membranes.
Botiss Biomaterials follows Geistlich and acts as the second-leading competitor in the total DBGS market. The company continues to experience significant growth, largely owing to its distribution deal established with Straumann Group, a leading dental implant manufacturer. Botiss has a presence in the allograft market which iT expects to generate promising growth from. This is especially true because of the growing acceptance of allograft products in the European market.
Zimmer Biomet comes in as the third-leading competitor. This company sold both DBGS material and dental barrier membranes, and it is the exclusive distributor of RTI Biologics’ dental regenerative products. Zimmer now offers an extensive portfolio of Puros® products, including cortical particulate, cortico-cancellous particulate, cancellous particulate, Ci particulate, DBM particulate, block allograft, and allograft putties, covering an exhaustive suite of allograft offerings.